

# CITATION REPORT

List of articles citing

Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective

DOI: 10.1016/j.rmed.2018.10.024

Respiratory Medicine, 2018, 145, 130-137.

**Source:** <https://exaly.com/paper-pdf/70823560/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial. <i>International Journal of COPD</i> , <b>2019</b> , 14, 2681-2695	3	5
4	Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 923-935	4	2
3	Add-on umeclidinium cost effective in COPD in the UK. <i>PharmacoEconomics &amp; Outcomes News</i> , <b>2018</b> , 818, 4-4	0.1	
2	Early computed tomography coronary angiography in adults presenting with suspected acute coronary syndrome: the RAPID-CTCA RCT. <b>2022</b> , 26, 1-114		1
1	Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review. 1-18		0